QIAGEN US : Q1 disappointing, but concerns over Roche TB look overdone

Research evidence excerpt

QIAGEN US : Q1 disappointing, but concerns over Roche TB look overdone

port) locally with in the condition

that parties should sign an agreement including the services to be provided and terms and conditions of the services and obtain required permissions

from local regulators if necessary. Otherwise, all such activities by BNP Paribas S.A. should be on a “reverse inquiry” basis.

United Arab Emirates (excluding the Dubai International Financial Centre (DIFC) and the Abu Dhabi Global Market (ADGM): In accordance with

Decision No (13/R.M) of 2021 on the Financial Activities Rulebook and Mechanisms of Adjustment of the Securities and Commodities Authority (SCA), as

amended (the SCA Rulebook), the securities to which this document relates may only be promoted in the UAE (excluding the DIFC and ADGM) as follows:

without the prior approval of SCA, only in so far as the promotion is directed to: a person who meets the definition of a “professional investor” under the

SCA Rulebook; or (ii) following a ‘reverse’ (i.e., unsolicited) enquiry by an investor. Further, this report does not constitute a public offer of securities in the

United Arab Emirates (including the DIFC and the ADGM) and is not intended to be a public offer. The SCA has not verified the report or other documents

in connection with the securities that are discussed therein. Accordingly, the SCA has not approved this report or any other associated documents nor taken

any steps to verify the information set out in this report. The SCA may not be held liable for the accuracy or completeness of the information in the report.

The securities to which this report relates may be illiquid or subject to restrictions on their resale. Prospective investors should conduct their own due

diligence on the such securities.